Evidence map›Paper›PMID 21063417›Full record

ArticleBritish journal of cancer2011

Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients.

M H Nieuwenhuis, E M Mathus-Vliegen, C G Baeten, F M Nagengast, J van der Bijl, A D van Dalsen, J H Kleibeuker, E Dekker, A M Langers, J Vecht and 7 more

Registry-linked trialOpen access · hybridAbstract readEvaluation Study
In one paragraph

Article in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02354560 (Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02354560 phase4unknown statusnot on this mapstarted 2015, after this paper: background citation

Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version

TypeinterventionalSponsormichal rollRan2015 to 2017Enrolled15ConditionsFAP-Familial Adenomatous PolyposisArmsErythromycin
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. The Role of Radiation Therapy for Symptomatic Desmoid Tumors.Current treatment options in oncology · 2021
    Review
  11. Review
  12. The Management of Desmoid Tumors: A Retrospective Study of 30 Cases.International journal of surgical oncology · 2020
    Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 1 country.

M H NieuwenhuisThe Netherlands Foundation for the Detection of Hereditary Tumours, Rijnsburgerweg 10, Poortgebouw Zuid, 2333 AA Leiden, The Netherlands. m.nieuwenhuis@stoet.nl
E M Mathus-Vliegen
C G Baeten
F M Nagengast
J van der Bijl
A D van Dalsen
J H Kleibeuker
E Dekker
A M Langers
J Vecht
F T Peters
R van Dam
W G van Gemert
W N Stuifbergen
W R Schouten
H Gelderblom
H F A Vasen
Maastricht University Medical Centre · NLAcademic Medical Center · NLIsala · NLLeiden University · NLNetherlands Consortium for Healthy Ageing · NLAtrium Medisch Centrum Parkstad · NLElisabeth-TweeSteden Ziekenhuis · NLErasmus University Rotterdam · NLRadboud University Nijmegen · NLUniversity Medical Center Groningen · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe optimal treatment of desmoid tumours is controversial. We evaluated desmoid management in Dutch familial adenomatous polyposis (FAP) patients.

methodsSeventy-eight FAP patients with desmoids were identified from the Dutch Polyposis Registry. Data on desmoid morphology, management, and outcome were analysed retrospectively. Progression-free survival (PFS) rates and final outcome were compared for surgical vs non-surgical treatment, for intra-abdominal and extra-abdominal desmoids separately. Also, pharmacological treatment was evaluated for all desmoids.

resultsMedian follow-up was 8 years. For intra-abdominal desmoids (n=62), PFS rates at 10 years of follow-up were comparable after surgical and non-surgical treatment (33% and 49%, respectively, P=0.163). None of these desmoids could be removed entirely. Eventually, one fifth died from desmoid disease. Most extra-abdominal and abdominal wall desmoids were treated surgically with a PFS rate of 63% and no deaths from desmoid disease. Comparison between NSAID and anti-estrogen treatment showed comparable outcomes. Four of the 10 patients who received chemotherapy had stabilisation of tumour growth, all after doxorubicin combination therapy.

conclusionFor intra-abdominal desmoids, a conservative approach and surgery showed comparable outcomes. For extra-abdominal and abdominal wall desmoids, surgery seemed appropriate. Different pharmacological therapies showed comparable outcomes. If chemotherapy was given for progressively growing intra-abdominal desmoids, most favourable outcomes occurred after combinations including doxorubicin.

Indexed as

ColectomyAdenomatous Polyposis ColiAdolescentAdultAntineoplastic AgentsCombined Modality TherapyDesmoid TumorsFemaleFibromatosis, AbdominalHumansIncidenceMaleMiddle AgedNetherlandsRadiotherapy DosageRetrospective StudiesAntineoplastic Agents

Identifiers

PMID21063417
PMCPMC3039799
OpenAlexW2146971290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.